Dyadic International, Inc. (DYAI)
Dyadic International, Inc. is a biotechnology company that specializes in the development and manufacturing of enzymes and microbial proteins using its proprietary C1 expression platform. The company focuses on providing solutions for various industries, including pharmaceuticals, bioenergy, agriculture, and food. Dyadic's technology enables efficient production of proteins at a large scale, supporting applications such as biopharmaceuticals, enzyme-based products, and industrial enzymes.
Company News
Dyadic International, Inc., a biotechnology company focused on large-scale protein manufacturing, announced it will report Q1 2025 financial results and host a corporate update call on May 14, 2025.
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer Announces Positive Results From Second Late-Stage Study Of Ulcerative Colitis Drug Pfizer, Inc. (NYSE: PFE) announced positive top-line results from a second Phase 3 study of etrasimod, which is being developed for the treatment of moderately ...
Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine candidate using Dyadic's C1 cells.
There were different reasons behind each of these COVID-19 vaccine stocks' big gains.
With earnings season in full swing, which penny stocks are investors watching right now? The post Best Penny Stocks to Buy Now? 4 to Watch During Earnings Season appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.